Daijiworld Media Network – New Delhi
New Delhi, Jul 24: Sarcomas, a rare group of cancers that develop in the body’s connective tissues such as bones, muscles, fat, cartilage, nerves and blood vessels, are witnessing major advances in diagnosis and treatment with the help of molecular diagnostics, precision medicine and artificial intelligence (AI).
Although sarcomas account for only a small percentage of all cancers, they are highly diverse, with more than 100 different subtypes. Each subtype has unique characteristics and may require different treatment approaches, making accurate diagnosis crucial.
Traditional treatments such as surgery, chemotherapy and radiation therapy continue to remain important in managing sarcomas. However, newer technologies are helping doctors understand these tumours better and provide more personalised care.
One of the biggest challenges in treating sarcoma is its complexity. Two tumours that appear similar on scans may behave differently due to differences in their biology. Doctors now rely on a combination of imaging, biopsy, histopathology and molecular testing to identify the exact subtype and plan suitable treatment.
Molecular diagnostics has improved the ability to detect genetic and chromosomal changes in cancer cells. In certain sarcoma cases, identifying specific molecular abnormalities can help confirm diagnosis and provide valuable information for treatment planning.
Precision medicine is also changing the way sarcomas are managed. Instead of using the same approach for all patients, doctors can now consider the individual characteristics of a tumour while deciding treatment options.
For some patients, targeted therapies aimed at specific genetic changes may be beneficial, while others may continue to require surgery, chemotherapy or radiation therapy. The aim is to select the treatment most likely to work for each patient rather than applying a one-size-fits-all approach.
Artificial intelligence is emerging as another supportive tool in sarcoma care. AI technology can assist doctors in analysing medical images, identifying patterns in pathology slides and combining information from different diagnostic tests.
While AI is still developing, experts believe it could help improve diagnostic accuracy, support treatment decisions and identify patients who may benefit from clinical trials. However, it will continue to serve as a support system for doctors rather than replacing medical expertise.
Due to the rare and complex nature of sarcomas, specialists emphasise the importance of multidisciplinary care involving orthopaedic oncologists, medical oncologists, radiation specialists, pathologists and radiologists.
Treatment at specialised centres can help patients access expert opinions, advanced diagnostic facilities and newer therapies when suitable.
With continued research, the future of sarcoma care is expected to become increasingly personalised. Advances in molecular testing, precision medicine and AI are paving the way for more accurate diagnosis and improved treatment strategies for patients battling these rare cancers.